Medical/Pharmaceuticals
HKSH Medical Group to Host Hong Kong's First Asia-Oceania Particle Therapy Co-operative Group Conference
Best Practice by World-class Experts in Proton Therapy Transforming Precision Cancer Management HONG KONG, Oct. 21, 2025 /PRNewswire/ -- HKSH Medical Group (HKSH) introduced Hong Kong's only and the Greater Bay Area's first proton therapy system in 2023, after two decades of planning and prepara...
2025-10-21 16:02
1389
Getinge Interim Report July-September 2025: High organic sales growth and stronger margins despite geopolitical headwinds
GOTHENBURG, Sweden, Oct. 21, 2025 /PRNewswire/ -- "We demonstrated strength in the third quarter with significant organic growth, improved profitability and cash flow despite impacts from tariffs and negative currency effects," says Mattias Perjos, President & CEO, Getinge. The medtech company's ...
2025-10-21 14:45
1285
Abbott and BIG CARiNG Group Launch Nationwide Influenza Awareness Program to Strengthen Public Health Response Through Early Intervention
KUALA LUMPUR, Malaysia, Oct. 21, 2025 /PRNewswire/ -- Abbott, a global healthcare leader, and BIG CARiNG Group (BCG), one ofMalaysia's largest retail pharmacies, announced a strategic three-year collaboration to promote influenza awareness acrossMalaysia. The Influenza Awareness Program, running ...
2025-10-21 13:12
1815
Google AI Breakthrough Highlights Silmitasertib (CX-4945) as a Novel Pathway in Cancer Immunotherapy
TAIPEI and SAN DIEGO, Oct. 20, 2025 /PRNewswire/ -- Senhwa Biosciences's investigational new drug Silmitasertib (CX-4945) was recently featured in an official post by Google DeepMind, following a major breakthrough by the tech giant's biological artificial intelligence (AI) system. DeepMind re...
2025-10-21 10:49
1158
SK Biopharmaceuticals Launches Joint Venture with Eurofarma for AI-based Epilepsy Management Platform
SK Biopharmaceuticals forms a joint venture, Mentis Care, to develop an integrated epilepsy care ecosystem through AI-driven platform commercialization. SEOUL, South Korea, Oct. 20, 2025 /PRNewswire/ -- SK Biopharmaceuticals, Co., Ltd., a biotech company focusing on research, development, and co...
2025-10-21 09:20
1254
LabConnect Featured in Season Finale of Emmy-Nominated Series Tomorrow's World Today
JOHNSON CITY, Tenn., Oct. 21, 2025 /PRNewswire/ -- LabConnect, a leading provider of global central laboratory and support services for clinical trials, will be featured on the season 9 finale of the innovation-focused TV series, Tomorrow's World Today. Premiering on Science Channel on November 8,...
2025-10-21 01:11
1033
TraceLink Recognized on Fast Company's Next Big Things in Tech List
The annual list honors groundbreaking advancements redefining the way we work and live BOSTON, Oct. 20, 2025 /PRNewswire/ -- TraceLink, the largest end-to-end digital network platform for intelligent orchestration of the supply chain, today announced its inclusion in Fast Company'sNext Big Thing...
2025-10-20 23:59
1046
WellsCare Partners with Celltrion Canada to Bring Advanced Wearable Pain Relief Tech to North America
SEOUL, South Korea, Oct. 20, 2025 /PRNewswire/ -- WellsCare, a South Korean medical technology startup, announced that onOctober 9, it signed a Memorandum of Understanding (MOU) with Celltrion Canada, a subsidiary of the global biopharmaceutical leader Celltrion. This strategic partnership is set...
2025-10-20 21:00
1516
BTL's EMSCULPT NEO Used in Astronaut Training in Hungary for International Space Mission
PRAGUE, Oct. 20, 2025 /PRNewswire/ -- BTL, a global leader in medical technologies, proudly announces that its flagship device, EMSCULPT NEO, played a key role in astronaut preparation ahead of a historic spaceflight. As a result of the cooperation between BTL Hungary and HUNOR (Hungarian To Orbi...
2025-10-20 20:09
1278
Exploring the Next Era of Cell & Gene Therapy with Nobel Laureate in London
PISCATAWAY, N.J., Oct. 20, 2025 /PRNewswire/ -- London will become the global spotlight for cell and gene therapy (CGT) this November as Nobel Laureate, scientific leaders, biotech innovators, and top investors convene to chart the future of one of the fastest-growing fields in emerging medicine....
2025-10-20 19:43
965
HanchorBio Showcases Pipeline Momentum with HCB101 and HCB301 Data Across Five Major Oncology Meetings in Q4 2025
Presentations highlight HCB101's differentiated profile and introduce first preclinical data from HCB301, underscoring HanchorBio's innovation in next-generation immunotherapies TAIPEI, SHANGHAI and SAN FRANCISCO, Oct. 20, 2025 /PRNewswire/ -- HanchorBio Inc. (TPEx: 7827), a global clinical-stag...
2025-10-20 19:00
1352
Groundbreaking Study in the Journal of Clinical Investigation Advances Cell Therapy for Huntington's Disease Treatment
SHANGHAI, Oct. 20, 2025 /PRNewswire/ -- The research team led by Dr. Yuejun Chen , founder of UniXell Biotech, published online an article titled "3D-Cultured Human Medium Spiny Neurons Achieve Functional Integration into Huntingtin Disease Mouse Neural Circuits and Improve Motor Deficits" in the ...
2025-10-20 18:13
916
The New England Journal of Medicine Publishes Results of Phase III OptiTROP-Lung04 Study of Sacituzumab Tirumotecan in Advanced EGFR-TKI-Resistant NSCLC
* After a median follow-up of 18.9 months, the median PFS was 8.3 months in the sac-TMT group and 4.3 months in the chemotherapy group (hazard ratio (HR), 0.49; 95% confidence interval (CI), 0.39 to 0.62; two-sided P<0.0001). * OS was significantly longer with sac-TMT than with chemotherapy (H...
2025-10-20 17:06
1309
ESMO Congress 2025 Presidential Symposium Oral Presentation | Disitamab Vedotin Achieves Major Breakthrough as First-Line Treatment for Urothelial Carcinoma
BERLIN, Oct. 20, 2025 /PRNewswire/ -- At the 2025 European Society for Medical Oncology (ESMO) Congress, a Phase III clinical study on disitamab vedotin plus toripalimab versus chemotherapy as first-line treatment for HER2-expressing locally advanced or metastatic urothelial carcinoma (RC48-C016)...
2025-10-20 14:58
1524
Live from ESMO | Hengrui Debuts Exhibition Booth with Landmark Data Showcasing Pharma's Emerging Innovation Power
BERLIN, Oct. 20, 2025 /PRNewswire/ -- From October 17 to 21, the European Society for Medical Oncology (ESMO) Annual Congress convened inBerlin, bringing together global leaders in oncology and pharmaceutical innovation. Representing China's advancing biopharmaceutical landscape, Hengrui Pharma no...
2025-10-20 14:20
1099
Accord Plasma B.V. Expands Global Plasma Therapy Capabilities with Acquisition of Prothya Biosolutions
LONDON, Oct. 20, 2025 /PRNewswire/ -- Accord Plasma B.V., a subsidiary of Intas Pharmaceuticals, announced today that it has successfully completed the acquisition of Prothya Biosolutions Belgium BV and its subsidiaries. This strategic move enhances Accord B.V.'s commitment to improving global a...
2025-10-20 14:00
1256
Kelun-Biotech Presents Positive Phase 3 Data for Trastuzumab Botidotin Compared to T-DM1 at 2025 ESMO
CHENGDU, China, Oct. 20, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that at the 2025 European Society for Medical Oncology (ESMO) Congress held inBerlin, Germany, Results from a Phase 3 study of the Company's human epidermal growth factor rece...
2025-10-20 13:59
1222
Biparatopic HER2-targeting ADC JSKN003 Was Granted Another Breakthrough Therapy Designation for HER2-Positive Advanced Colorectal Cancer
SUZHOU, China, Oct. 20, 2025 /PRNewswire/ -- October 20, 2025- Alphamab Oncology (stock code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (Stock Code: 1093.HK) jointly announced that biparatopic HER2-targeting antibody-drug conjugate (ADC) JSKN003 has been granted another breakthrou...
2025-10-20 13:21
1164
Alphamab Oncology Presented Multiple Clinical Data on Biparatopic HER2-targeting ADC JSKN003 at ESMO Congress 2025
SUZHOU, China, Oct. 20, 2025 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that two latest clinical data on biparatopic HER2-targeting antibody-drug conjugate (ADC) JSKN003 for the treatment of primary platinum-refractory ovarian cancer (OC) and HER2-positive metastatic colore...
2025-10-20 13:15
1279
Positive Results from Phase 3 OptiTROP-Lung04 Trial of Sacituzumab Tirumotecan Presented at ESMO Presidential Symposium and Simultaneously Published in NEJM
CHENGDU, China, Oct. 20, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that at the 2025 European Society for Medical Oncology (ESMO) Congress held inBerlin, Germany, results from a Phase 3 OptiTROP-Lung04 trial of the Company's trophoblast cell-s...
2025-10-20 10:36
1253
Week's Top Stories
Most Reposted
Visa Supports Chinese Cardholders to Add Cards to Apple Pay for a More Convenient and Secure Payment Experience
[Picked up by 310 media titles]
2026-01-15 13:00Colebrook Bosson Saunders Launches Lana: An Adaptable Laptop Stand Engineered for Hybrid Work
[Picked up by 305 media titles]
2026-01-12 16:16
Ready Server Announces Strategic Expansion into Japan with AT TOKYO Data Centre
[Picked up by 301 media titles]
2026-01-13 13:16
CAYIN AI: Revolutionizing Creativity and Global Communication
[Picked up by 300 media titles]
2026-01-12 16:34
JIOS Aerogel® Secures Hyundai Contract Through New Licensing Model
[Picked up by 299 media titles]
2026-01-15 10:00Most Read
TCL Earns Multiple CES 2026 Awards for Breakthrough Innovations Across TV, Mobile, and Smart Home Categories
2026-01-10 01:00
5485
CATL Opens Middle East's Largest New Energy Aftermarket Facility in Riyadh
2026-01-11 04:10
4502
